Ionis Pharmaceuticals Inc (MIL:1IONS) Share Price

Company Profile

Business description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Contact
2855 Gazelle Court
CarlsbadCA92010
USA
T: +1 760 931-9200
E: [email protected]
https://www.ionis.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,402

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,935.00	14.40	-0.16%
CAC 40	8,156.92	15.00	0.18%
DAX 40	24,100.75	17.22	0.07%
Dow JONES (US)	49,167.79	62.92	-0.13%
FTSE 100	10,360.98	39.89	0.39%
HKSE	25,679.78	245.87	-0.95%
NASDAQ	24,887.10	50.50	0.20%
Nikkei 225	59,917.46	619.90	-1.02%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,173.91	8.83	0.12%
S&P/ASX 200	8,710.70	10.50	-0.12%
SSE Composite Index	4,078.64	7.71	-0.19%